Q3 Healthcare Report Cites Federal Research Cuts and FDA Staff Losses as Pressures on Biotech
By Andy Studna
November 18, 2026
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Investment bank Cassel Salpeter & Co. cites federal funding cuts, staffing losses at the FDA, and tariffs as pressures on the US biotech industry in its Q3 2026 healthcare update. In a section titled “Is the Government Strangling Biotech?”, the report looks at how government policy affects drug development and the companies behind it.1
The National Institutes of Health (NIH) is central to the report’s discussion of government’s role. It describes the NIH as the government’s most important contribution to the biotech ecosystem and says the agency has funded “almost $200 billion in laboratory and clinical research” since 2021. That research has produced technologies and molecules that became the basis for new companies or were licensed or sold to biotech firms.
Pressure on grants and training
The report states that the administration continues to push for control of and cuts to research spending. Congress has resisted some of those demands, it says, but some cuts have been made. Grant processing has also been disrupted, including new applications and renewals of grants and contracts, which adds pressure on research and training programs.
Clinical research infrastructure is part of that picture. The report notes that National Cancer Institute (NCI)-designated cancer centers train oncologists and clinical scientists and host clinical trials, and that NIH money supports graduate and postdoctoral training programs, which it describes as “farm clubs” for the industry. Cuts to training grants and fewer visas for foreign workers may make it harder to staff new US facilities.
FDA losses and a tougher financing climate
At the FDA, the report says the agency has lost more than 3,500 employees since January 20, 2025, including 800 from the Center for Drug Evaluation and Research (CDER) and almost 400 from the Center for Biologics Evaluation and Research (CBER). Almost 1,000 additional staffers resigned or took early retirement, including senior scientists and administrators. The report states that the cuts have caused major disruptions to drug development and approval and may affect the safety of the nation’s drug supply.
Click here to read the full article.


